Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Change in Account Payables (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Change in Account Payables for 14 consecutive years, with -$1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 105.47% year-over-year to -$1.4 million, compared with a TTM value of -$1.1 million through Dec 2025, down 155.65%, and an annual FY2025 reading of -$1.1 million, down 155.65% over the prior year.
  • Change in Account Payables was -$1.4 million for Q4 2025 at Karyopharm Therapeutics, down from $2.8 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $6.3 million in Q1 2023 and bottomed at -$6.8 million in Q2 2023.
  • Average Change in Account Payables over 5 years is -$22350.0, with a median of -$703500.0 recorded in 2021.
  • The sharpest move saw Change in Account Payables tumbled 480.73% in 2021, then skyrocketed 322.17% in 2024.
  • Year by year, Change in Account Payables stood at $722000.0 in 2021, then soared by 171.47% to $2.0 million in 2022, then grew by 11.22% to $2.2 million in 2023, then tumbled by 131.01% to -$676000.0 in 2024, then tumbled by 105.47% to -$1.4 million in 2025.
  • Business Quant data shows Change in Account Payables for KPTI at -$1.4 million in Q4 2025, $2.8 million in Q3 2025, and -$3.3 million in Q2 2025.